Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics plc (NASDAQ: AKTX) is an oncology biotechnology company whose news flow centers on the development of its PH1-based antibody–drug conjugates (ADCs). Company updates frequently highlight progress with its lead Trop2-targeting ADC, AKTX-101, and the broader PH1 spliceosome-modulating payload platform designed to disrupt RNA splicing in cancer cells and activate immune responses.
Investors following AKTX news can expect regular announcements on preclinical data, particularly in hard-to-treat solid tumors such as KRAS-mutant pancreatic ductal adenocarcinoma, urothelial (bladder) cancer, and gastric cancer. Akari’s releases often describe new efficacy and safety findings for AKTX-101, including comparisons with ADCs that use traditional payloads and exploratory work on synergy with checkpoint inhibitors.
Another recurring news theme is platform and pipeline development. Akari reports on the evolution of its ADC discovery platform, the advancement of additional candidates like AKTX-102 for GI and lung cancers, and scientific engagement through conference presentations and virtual investor segments such as its “CEO Corner” and “What This Means” features.
On the corporate side, Akari’s news includes financing transactions, such as registered direct offerings, private placements with warrants, and note exchanges that the company states are intended to fund research and development, working capital, and general corporate purposes. Updates on manufacturing partnerships, including GMP manufacturing of AKTX-101 with WuXi XDC, and disclosures related to Nasdaq listing requirements also appear in its news stream.
For readers tracking oncology innovation and early-stage ADC pipelines, the AKTX news page offers a focused view of how Akari is progressing its PH1 payload technology, preparing for potential clinical trials, and managing the capital and governance steps that support its development plans.
Akari Therapeutics (Nasdaq: AKTX) has secured approximately $4 million in gross proceeds through a direct offering involving institutional and accredited investors, including its Board of Directors. The company will issue around 26.67 million American Depository Shares (ADSs) at a price of $0.15 per ADS. Proceeds will fund two key pipeline initiatives: advancing a Phase 3 trial for nomacopan in severe pediatric conditions and a preclinical study for geographic atrophy. The offering excludes warrants and is expected to close on March 31, 2023.
Akari Therapeutics (Nasdaq: AKTX) has announced that regulatory agencies in Poland and the U.K. approved amendments to its Investigational Medicinal Product Dossier and Clinical Trial Authorisation for the third-generation manufacturing process of nomacopan, which significantly boosts its yield by at least 5-fold. This enhancement is set to improve cost efficiencies as Akari moves into pivotal Part B of the Phase 3 clinical trial for nomacopan, targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The trial includes sites in Poland, the U.K., and the U.S.
The 'Asthma Pipeline Insight – 2023' report by DelveInsight reveals a dynamic landscape in asthma therapies, highlighting over 90 active pharmaceutical players developing more than 95 pipeline treatments. Key companies include GlaxoSmithKline, AstraZeneca, and Verona Pharma. Notably, dexpramipexole received an Innovation Passport from the UK's MHRA and is entering Phase III trials. Additionally, Pulmatrix, Inc. initiated a Phase IIb trial for PUR1900, targeting Allergic Bronchopulmonary Aspergillosis. Olatec Therapeutics secured $40 million in Series A funding to advance dapansutrile into clinical development. This report offers insights into asthma clinical trials, therapeutic assessments, and drug mechanisms.
Akari Therapeutics (Nasdaq: AKTX) has made significant strides in its Phase 3 Part A clinical trial of nomacopan for pediatric HSCT-related thrombotic microangiopathy (HSCT-TMA). A case study presented on February 16 at a major transplantation conference highlighted the positive outcomes for a 6-year-old patient who showed improvement after receiving nomacopan treatment.
Notably, the patient achieved critical therapeutic milestones, including normalization of key biomarkers and resolution of related health complications. Nomacopan is recognized as a promising therapy in a field lacking approved options for severe cases, potentially addressing an 80% mortality rate in untreated patients.
Akari Therapeutics announced progress on its pre-clinical program for long-acting PAS-nomacopan, targeting geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). An Investigational New Drug (IND) application is set for submission to the FDA in the first half of 2024. The company filed a composition of matter patent application for long-acting versions, providing protection until 2042. The new PAS-nomacopan versions exhibit significant improvements, allowing for increased dosing intervals beyond three months, potentially reducing the need for frequent intravitreal injections.
Akari Therapeutics (Nasdaq: AKTX) has announced the progression into Part B of its Phase 3 clinical trial for nomacopan, targeting pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Following favorable FDA feedback indicating that pharmacokinetic/pharmacodynamic data from Part A aligns with predictions, Akari will advance its study for patients aged 2 to 18 years. To support this, a new pipeline program for adult HSCT-TMA treatment with nomacopan is being initiated, given the larger adult patient population. The company's prompt actions highlight a commitment to addressing unmet medical needs in both pediatric and adult demographics.
The paroxysmal nocturnal hemoglobinuria (PNH) market is projected to reach USD 1,100 million in 2021, with anticipated growth driven by rising cases and new therapies from major companies like Hoffmann-La Roche, Alexion, and Novartis. DelveInsight's report indicates approximately 12K prevalent cases in the 7MM (U.S., EU-4, U.K., Japan) as of 2021. Key pipeline therapies include Crovalimab and Iptacopan. Despite advancements, challenges like continuous hemolysis and the impending expiration of eculizumab patents in 2024 and 2027 could impact market dynamics. This report covers market trends through 2032, focusing on treatment efficacy, barriers, and emerging drugs.
On January 4, 2023, Akari Therapeutics (Nasdaq: AKTX) announced that President and CEO Rachelle Jacques will present at the Biotech Showcase 2023 on January 9 at 9 am ET. The presentation will cover significant updates on two pipeline programs: a Phase 3 trial of nomacopan for treating severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program for long-acting PAS-nomacopan targeting geographic atrophy. Akari is focused on therapies for autoimmune and inflammatory diseases.
Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm, announced participation in the Cantor Medical and Aesthetic Dermatology Conference in Miami on December 7-8, 2022. President and CEO Rachelle Jacques will join an ophthalmology panel on December 8, discussing 'Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up.' The management team will also conduct 1:1 investor meetings to address their pre-clinical program for long-acting PAS-nomacopan in geographic atrophy (GA). Akari's investigational drug, nomacopan, targets autoimmune diseases.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced participation in BTIG's Ophthalmology Day on November 29, 2022, with a fireside chat led by CEO Rachelle Jacques at 9:30 am ET. The company will discuss advancements in long-acting PAS-nomacopan for geographic atrophy (GA), highlighting positive pre-clinical results that may support moving towards IND/IMPD for clinical trials. Akari is focused on developing therapies for autoimmune and inflammatory diseases, with its lead candidate, nomacopan, having received several FDA designations for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.